carbidopa, levodopa drug combination has been researched along with Parkinson Disease, Secondary in 32 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (25.00) | 18.7374 |
1990's | 13 (40.63) | 18.2507 |
2000's | 3 (9.38) | 29.6817 |
2010's | 5 (15.63) | 24.3611 |
2020's | 3 (9.38) | 2.80 |
Authors | Studies |
---|---|
Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
Balogun, CI; Fatoki, AM; Oladimeji, S; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ; Onaolapo, TM | 1 |
Bolia, R; Panda, PK; Sharawat, IK; Shrivastava, Y | 1 |
Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A | 1 |
Chang, MC; Chun, MH; Kang, CG; Kong, EJ | 1 |
Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
Arami, MA; Ayromlou, H; Najmi, S | 1 |
Ahmad, M; Gupta, A; Rizvi, I; Zaidi, N | 1 |
Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
Delville, Y; Fleming, SM; Schallert, T | 1 |
Kamenetskiĭ, VK | 1 |
Lang, AE | 1 |
Lunn, V; Northcott, C; Yatham, LN | 1 |
Caligiuri, MP | 1 |
Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J | 1 |
Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B | 1 |
Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
Emerich, DF; Francis, JM; Lindner, MD; Plone, MA | 1 |
Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z | 1 |
Golubev, VL; Shtul'man, DR; Shvareva, IS; Veĭn, AM; Zhuchenko, TD | 1 |
Lapchak, PA | 1 |
Ahlskog, JE | 1 |
Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
Gash, DM; Kim, MH; Kurlan, R | 1 |
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
Jankovic, J | 1 |
Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 2 |
Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
Duvoisin, RC; Sage, JI | 1 |
Luque, FA; Petruska, P; Selhorst, JB | 1 |
4 review(s) available for carbidopa, levodopa drug combination and Parkinson Disease, Secondary
Article | Year |
---|---|
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed | 1995 |
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
28 other study(ies) available for carbidopa, levodopa drug combination and Parkinson Disease, Secondary
Article | Year |
---|---|
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Carbidopa; Chlorpromazine; Diet; Drug Combinations; Eating; Grooming; Levodopa; Lipid Peroxidation; Mice; Motor Activity; Parkinson Disease, Secondary; Pyridoxal Phosphate | 2020 |
Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent.
Topics: Adolescent; Antiparkinson Agents; Brain; Carbidopa; Dengue; Diffusion Magnetic Resonance Imaging; Drug Combinations; Electroencephalography; Humans; India; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Treatment Outcome | 2020 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly | 2021 |
Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage.
Topics: Activities of Daily Living; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drainage; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Positron-Emission Tomography; Predictive Value of Tests; Putamen; Radiopharmaceuticals; Recovery of Function; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tropanes; Ventriculoperitoneal Shunt | 2015 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Isolated extra pontine myelinolysis presenting as acute onset parkinsonism.
Topics: Acute Disease; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Saline Solution, Hypertonic | 2012 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
Parkinsonism and bipolar affective disorder.
Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary | 1995 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior | 1996 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior | 1997 |
[Vascular parkinsonism].
Topics: Antiparkinson Agents; Brain Ischemia; Carbidopa; Drug Combinations; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Ultrasonography, Doppler, Transcranial | 1998 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines | 1986 |
Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy.
Topics: Aged; Carbidopa; Cognition Disorders; Confusion; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1986 |
Parkinsonism induced by high-dose cytosine arabinoside.
Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1987 |